Tezepelumab for the treatment of chronic spontaneous urticaria: Results of the phase 2b INCEPTION study. McLaren J, Chon Y, Gorski KS, Bernstein JA, et al. J Allergy Clin Immunol 2025;155:1945-1956.

Read + Share

Amedeo Smart

Independent Medical Education

Read + Share

McLaren J, Chon Y, Gorski KS, Bernstein JA, et al. Tezepelumab for the treatment of chronic spontaneous urticaria: Results of the phase 2b INCEPTION study. J Allergy Clin Immunol 2025;155:1945-1956.
PMID: 39956278